Kolexia
Callens Celine Pharmacien
Callens Celine
Pharmacien
Clcc Institut Curie
Paris, France
130 Activités
53 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Carcinomes Leucémies Tumeurs du sein triple-négatives Anémie Adénocarcinome Tumeurs du poumon Métastase tumorale Leucémie-lymphome lymphoblastique à précurseurs T

Collaborateurs

Voir plus
Bieche Ivan
Bieche Ivan
Institut Curie, Saint-Cloud, France
Bidard Francois-Clement
Bidard Francois-Clement
Clcc Institut Curie, Paris, France
Vincent-Salomon Anne
Vincent-Salomon Anne
Clcc Institut Curie, Paris, France
Lerebours Florence
Lerebours Florence
Institut Curie, Saint-Cloud, France

Industries

Voir plus
AstraZeneca
5 collaboration(s)
Dernière en 2022
B3TSI
2 collaboration(s)
Dernière en 2020
Pfizer
2 collaboration(s)
Dernière en 2021
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Molecular and clinical portrait of HER2-low invasive lobular carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   28 février 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene   27 février 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
BMC biology   20 février 2024
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE): Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting
Essai Clinique (Institut Curie)   29 janvier 2024
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
Oncogene   09 novembre 2023
351TiP EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
Clinica chimica acta; international journal of clinical chemistry   25 avril 2023
Hereditary cancer predispositions: Comparison of multigene panel sequencing on fresh-frozen breast/ovarian tumor versus blood.
Clinical genetics   27 mars 2023